Samer Al Hadidi/LinkedIn
Mar 17, 2025, 14:20
Samer Al Hadidi: Longest follow up of phase III clinical trials in myeloma
Samer Al Hadidi, Assistant professor at UAMS Myeloma Center, shared an article on X:
“Longest follow up of phase III clinical trials in myeloma.
- Median survival >13 years.
- 41% of patients remained disease free and off therapy with fixed-duration therapy in standard-risk MM.
- Myeloma is curable for a subset of patients.”
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma.
Authors: Samer Al Hadidi
More posts featuring Samer Al Hadidi.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 29, 2025, 19:09
May 29, 2025, 17:58
May 29, 2025, 17:45
May 29, 2025, 17:39